MedTrace Logo

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

NCT00523809 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2013-01-28

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if giving Avastin (bevacizumab) with standard chemotherapy and a blood stem cell transplant, in patients with an advanced solid tumor, can help to shrink the tumor or slow its growth. The safety of this treatment will also be studied.

Conditions

Interventions

DRUG

Bevacizumab

10 mg/kg IV Daily Over 30 Minutes for 1 Day

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Stem Cell Transplantation on Day 8.

DRUG

Fludarabine

25 mg/m\^2 IV Daily Over 30 Minutes for 5 Days

DRUG

Melphalan

70 mg/m\^2 IV Daily Over 30 Minutes for 2 Days

DRUG

Thymoglobulin

0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Naoto Ueno, MD, PhD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00523809 on ClinicalTrials.gov